Skip to main content

Advertisement

Table 1 Relationship between p53 and Δp53 mutation status and their correlation to biological and clinical factors

From: Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters

    Wild type (Wt) Wt Δp53 Wt p53 Mutational hybrid Wt Δp53 M p53 Mutations (MI = MS, IF) MI Δp53 MI p53 Mutations (MII = NS, FS, SP, SC) MII Δp53 MII p53   
Characteristic Total No.   No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%) Groups p
Lymph node status 88 Node-negative 16 32.0 1 9.1 4 23.5 6 60.0 WtWt-WtM 1 n.s.
   Node-positive 34 68.0 10 90.9 13 76.5 4 40.0 WtM-MIMI 1 n.s.
            WtM-MM 1 n.s. ( p < 0.09)
            WtWt-WtM-MM 2 n.s.
            WtWt-WtM-MIMI-MIIMII 2 n.s. ( p < 0.08)
Estrogen receptor status 88 Negative 10 20.0 3 27.3 8 47.1 3 30.0 WtWt-WtM 1 n.s.
   Positive 40 80.0 8 72.7 9 52.9 7 70.0 WtM-MIMI 1 n.s.
            WtM-MM 1 n.s.
            WtWt-WtM-MM 2 n.s.
            WtWt-WtM-MIMI-MIIMII 2 n.s.
Progesterone receptor status 88 Negative 13 26.0 4 36.4 9 52.9 6 60.0 WtWt-WtM 1 n.s.
   Positive 37 74.0 7 63.6 8 47.1 4 40.0 WtM-MIMI 1 n.s.
            WtM-MM 1 n.s.
            WtWt-WtM-MM 2 p < 0.04
            WtWt-WtM-MIMI-MIIMII 2 n.s. ( p < 0.09)
ERBB2/HER status 60 Negative 29 80.6 5 62.5 10 90.9 1 20.0 WtWt-WtM 1 n.s.
   Positive 7 19.4 3 37.5 1 9.1 4 80.0 WtM-MIMI 1 n.s.
            WtM-MM 1 n.s.
            WtWt-WtM-MM 2 n.s.
            WtWt-WtM-MIMI-MIIMII 2 p < 0.02
Distant metastisis at time of diagnosis 65 Negative 30 90.9 7 77.8 15 100.0 7 87.5 WtWt-WtM 1 n.s.
   Positive 3 9.1 2 22.2 0 0.0 1 12.5 WtM-MIMI 1 n.s. ( p < 0.07)
            WtM-MM 1 n.s.
            WtWt-WtM-MM 2 n.s.
            WtWt-WtM-MIMI-MIIMII 2 n.s.
Grade 88 1 5 10.0 0 0.0 0 0.0 0 0.0 WtWt-WtM 1 n.s.
   2 24 48.0 4 36.4 4 23.5 4 40.0 WtM-MIMI 1 n.s.
   3 21 42.0 7 63.6 13 76.5 6 60.0 WtM-MM 1 n.s.
            WtWt-WtM-MM 2 p < 0.03
            WtWt-WtM-MIMI-MIIMII 2 p < 0.05
Response to chemotherapy 54 Response 24 92.3 8 88.9 9 81.8 5 62.5 WtWt-WtM 1 n.s.
   None response 2 7.7 1 11.1 2 18.2 3 37.5 WtM-MIMI 1 n.s.
            WtM-MM 1 n.s.
            WtWt-WtM-MM 2 n.s.
            WtWt-WtM-MIMI-MIIMII 2 n.s.
Subgroups* 84 Luminal A 25 53.2 2 18.2 2 12.5 0 0.0 WtWt-WtM 1 n.s. ( p < 0.08)
   Luminal B 6 12.8 2 18.2 4 25.0 3 30.0 WtM-MIMI 1 n.s.
   ERBB2 7 14.9 3 27.3 4 25.0 4 40.0 WtM-MM 1 n.s.
   Basal 4 8.5 4 36.4 6 37.5 2 20.0 WtWt-WtM-MM 2 p < 0.008
   Normal-like 5 10.6 0 0.0 0 0.0 1 10.0 WtWt-WtM-MIMI-MIIMII 2 p < 0.02
  1. MS = missense mutations, NS = nonsense mutations, FS = frame shift mutations, IF = in frame mutations, SP = splice mutations, SC = Δp53 splice cassette mutations
  2. M = MI + MII
  3. 1 for WtWt-WtM, WtM-MIMI and WtM-(MIMI+MIIMII) the Mann-Whitney test was performed
  4. 2 for WtWt-WtM-(MIMI+MIIMII) and WtWt-WtM-MIMI-MIIMII the Kruskal Wallis test was performed
  5. * The tumors have previously been subjected to whole genome microarray analysis and classified into subgroups according to their expression profile (see Material and Methods)